Press ReleaseFor Immediate Release
5 January 2026
Taipei Heart Institute Announces Participation in APSC STEMI Pilot Study Call
In Collaboration with Three Affiliated Hospitals to Strengthen STEMI Patient Recruitment and Outcomes
Taipei, Taiwan — 5 January 2026 — Taipei Heart Institute is pleased to announce its commitment to the Asian Pacific Society of Cardiology (APSC) STEMI Pilot Study Call, joining forces with three affiliated hospitals to collaboratively support clinical recruitment and research efforts in ST-segment elevation myocardial infarction (STEMI) care across the Asia-Pacific region.
Acute ST-segment elevation myocardial infarction (STEMI) is a critical cardiovascular emergency with substantial morbidity and mortality worldwide. In Taiwan, single-centre reports estimate annual STEMI case volumes of approximately 70–80 patients per year, with observed mortality rates in the range of 5–10%, underscoring the urgent need for improved clinical evidence and collaborative research. Collaborating across multiple sites significantly reduces the burden of recruitment for each hospital to achieve target enrolment in the pilot study.
The APSC STEMI Pilot Study aims to evaluate and refine new clinical strategies for STEMI management and outcomes, emphasizing real-world applicability, quality of care, and evidence generation for future large-scale trials. As part of this pilot programme, each participating site is expected to recruit 50 patients in the first phase. By combining resources and patient cohorts across institutions, Taipei Heart Institute and its partners will optimize patient accrual, share operational responsibilities, and enhance the statistical power of the pilot study.
“Our participation in the APSC STEMI Pilot Study reflects our institute’s dedication to advancing collaborative cardiovascular research and delivering better outcomes for STEMI patients,” said a representative of Taipei Heart Institute. “Pooling expertise and patient resources across hospitals will enable us to more effectively meet recruitment goals while maintaining high standards of clinical care and data quality.”
Joining Taipei Heart Institute in this initiative are three affiliated hospitals (names to be announced), representing a broad network of interventional cardiology and STEMI care providers committed to improving acute myocardial infarction management in Taiwan and the wider Asia-Pacific region.
Through this collaborative effort, Taipei Heart Institute and partner hospitals aim to generate meaningful pilot data that will inform future regional and global STEMI research, contribute to guideline development, and ultimately enhance patient survival and quality of care.